Payment overview · 2025
General Payments
$4,166.08
187 reported records · 36 companies
Healthcare provider profile · identity verified
Graciany Miranda, MD.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · HUMACAO, PR · NPI 1386639995
Verified facts
What the public records show
CMS Open Payments records show Graciany Miranda, MD. received $4,166.08 in general payments during 2025 across 187 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 78 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Erleada, Keytruda, Kisqali, Lupron Depot, Opdivo, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Xtandi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Calquence by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Opdivo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Sprycel by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Imbruvica by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 790 records involving 308 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Erleada by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Keytruda by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kisqali by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Promacta by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 328 records involving 103 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Xtandi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Xtandi by this doctor in 2024.
TOLMAR, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIGARD as an associated drug or biological on 5834 records involving 3291 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eligard by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $585.52 | 14.1% | 23 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $476.61 | 11.4% | 22 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $423.94 | 10.2% | 18 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $345.39 | 8.3% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.79 | 7.5% | 17 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $229.97 | 5.5% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $225.52 | 5.4% | 10 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $184.06 | 4.4% | 8 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $177.62 | 4.3% | 6 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $150.50 | 3.6% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.69 | 2.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $94.26 | 2.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $89.60 | 2.1% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $77.99 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.42 | 1.9% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $76.81 | 1.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $75.81 | 1.8% | 3 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $47.47 | 1.1% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.36 | 1.1% | 2 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $39.24 | 0.9% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $28.59 | 0.7% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.00 | 0.6% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $24.98 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.95 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.94 | 0.6% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $24.53 | 0.6% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $23.67 | 0.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.18 | 0.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.95 | 0.5% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.74 | 0.4% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $17.74 | 0.4% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $17.73 | 0.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.63 | 0.4% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $15.06 | 0.4% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.91 | 0.3% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $13.91 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,998.10 | 185 |
| Education | $167.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $260.00 | 12 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $229.97 | 11 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $200.78 | 11 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PBG PUERTO RICO LLC | $163.90 | 8 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PBG PUERTO RICO LLC | $163.90 | 8 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $162.45 | 7 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $162.39 | 6 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PBG PUERTO RICO LLC | $160.43 | 6 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Puerto Rico Inc. | $150.50 | 6 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $149.20 | 6 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $142.46 | 6 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $139.21 | 5 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $137.85 | 7 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $124.20 | 5 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $118.96 | 5 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $101.34 | 4 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Pharmaceuticals, Inc | $101.09 | 7 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $100.63 | 4 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PBG PUERTO RICO LLC | $99.61 | 4 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Puerto Rico Inc. | $99.56 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $98.69 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $94.26 | 4 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $89.39 | 4 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $87.63 | 5 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $87.63 | 5 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $82.71 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $76.32 | 4 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $75.81 | 3 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $75.00 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PBG PUERTO RICO LLC | $74.61 | 3 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $74.34 | 7 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $71.87 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $71.52 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PBG PUERTO RICO LLC | $68.39 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $67.41 | 3 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $65.71 | 3 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | E.R. Squibb & Sons, L.L.C. | $61.51 | 3 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $54.06 | 3 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Puerto Rico Inc. | $50.94 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $47.47 | 2 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $41.55 | 4 | 2025 |
Source payment records
|
|||||
| IMDELLTRA (AMG757) Normalized: imdelltra amg757 |
Biological | Amgen Inc. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| LUMAKRAS Normalized: lumakras |
Drug | Amgen Inc. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| KYPROLIS Normalized: kyprolis |
Drug | Amgen Inc. | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| Phesgo Normalized: phesgo |
Biological | Genentech USA, Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| Columvi Normalized: columvi |
Biological | Genentech USA, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| ELELYSO Normalized: elelyso |
Drug | PBG PUERTO RICO LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Perjeta Normalized: perjeta |
Biological | Genentech USA, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PBG PUERTO RICO LLC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUPRON DEPOT lupron depot |
2025 | Lupron Depot | 2024 | 296 | exact normalized | Medicare Part D |
| OPDIVO opdivo |
2025 | Opdivo | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
296 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
122 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
122 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 790 supporting records · 308 recipient NPIs · example record 1174226359 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 328 supporting records · 103 recipient NPIs · example record 1228797041 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
122 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
122 | 13 |
| TOLMAR, INC. Exact reporting entity; no affiliate inference |
2025 | ELIGARD open payments reported associated product |
CMS Open Payments — General Payments 5834 supporting records · 3291 recipient NPIs · example record 1237000419 |
Eligard · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lupron Depot | Leuprolide Acetate | 296 | 47 |
| Hydroxyurea | Hydroxyurea | 133 | 19 |
| Xtandi | Enzalutamide | 122 | 13 |
| Retacrit | Epoetin Alfa-Epbx | 118 | 63 |
| Anastrozole | Anastrozole | 104 | 18 |
| Letrozole | Letrozole | 56 | suppressed |
| Sprycel | Dasatinib | 52 | suppressed |
| Erleada | Apalutamide | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 15 |
| Kisqali | Ribociclib Succinate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | suppressed |
| Eligard | Leuprolide Acetate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Calquence | Acalabrutinib Maleate | 25 | suppressed |
| Prolia | Denosumab | 22 | 13 |
| Docetaxel | Docetaxel | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Keytruda | Pembrolizumab | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 17 | suppressed |
| Imbruvica | Ibrutinib | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Opdivo | Nivolumab | 15 | suppressed |
| Zoledronic Acid | Zoledronic Acid/Mannitol-Water | 15 | 15 |
| Anagrelide Hcl | Anagrelide Hcl | 14 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 13 | suppressed |
| Fulvestrant | Fulvestrant | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Promacta | Eltrombopag Olamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,166.08 · 187 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, BESREMI, BLINCYTO, BOSULIF, BRAFTOVI, BREYANZI, BRUKINSA, CABOMETYX, CALQUENCE, Columvi, DARZALEX, ELAHERE, ELELYSO, ELREXFIO, EMRELIS, ENHERTU, EPKINLY, ERLEADA, Gavreto, IBRANCE, IMDELLTRA (AMG757), IMFINZI, INLYTA, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, KYPROLIS, LIBTAYO, LORBRENA, LUMAKRAS, LUPRON DEPOT, LUTATHERA, LYNOZYFIC, LYNPARZA, Lenvima, Lunsumio, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Orserdu, PADCEV, PEMAZYRE, PLUVICTO, Perjeta, Phesgo, Polivy, REBLOZYL, RUBRACA, RYBREVANT, Rezlidhia, SARCLISA, Stivarga, TAGRISSO, TALZENNA, TAVALISSE, Trelstar, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vitrakvi, Vonjo, Vyloy, WELIREG, XGEVA, XTANDI, ZYNYZ | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error